阿爾茨海默病與2型糖尿病第一頁(yè)，共20頁(yè)。大綱論文報(bào)告會(huì)01020304介紹相關(guān)研究藥物研究總結(jié)0101第二頁(yè)，共20頁(yè)。介紹阿爾茨海默?。ˋlzheimer'sDisease,AD）2型糖尿?。═ype2DiabetesMellitus,T2D）4680萬(wàn)↑億標(biāo)準(zhǔn)化患病率6.61%↑DM患病率11.6%,T2D占90%02神經(jīng)病理學(xué)特征：淀粉樣蛋白沉積造成的老年斑（senileplaque，SP）過(guò)磷酸化tau蛋白形成的神經(jīng)纖維纏結(jié)（neurofiberilarytangles,NFT）6,7第三頁(yè)，共20頁(yè)。大綱論文報(bào)告會(huì)01020304介紹相關(guān)研究藥物研究總結(jié)0203第四頁(yè)，共20頁(yè)。相關(guān)研究04流行病學(xué)研究分子機(jī)制研究研究名稱年份火奴魯魯-亞洲老年隊(duì)列2006PROSPER隊(duì)列2010ACCORD-MIND研究2014T2D是AD發(fā)病的危險(xiǎn)因素010302糖代謝紊亂血管因素胰島素通路受損分子機(jī)制研究01葡萄糖轉(zhuǎn)運(yùn)體(GlucoseTransporter,GLUT)減少糖基化終末產(chǎn)物(AdvancedGlycationEndProducts,AGEs)增多血腦屏障（BloodBrainBarrier,BBB）破壞腦血流量（CerebralBloodFlow,CBF）↓糖攝取↓BBB對(duì)Aβ清除率↓神經(jīng)元功能障礙蛋白質(zhì)沉積↑氧化應(yīng)激↑誘導(dǎo)炎癥反應(yīng)調(diào)節(jié)細(xì)胞周期RAGE結(jié)合Aβ→Aβ入腦↑02胰島素抵抗03GLUT微血管病變第五頁(yè)，共20頁(yè)。外周→腦內(nèi)血腦屏障葡萄糖炎癥因子炎癥因子TNF-α,IL1-β,IL-6神經(jīng)細(xì)胞胰島素抵抗胰島素受體（IR）線粒體ROSAGEsAβAGE受體（RAGE）Aβ胰島素競(jìng)爭(zhēng)05外周腦內(nèi)惡性循環(huán)→認(rèn)知障礙第六頁(yè)，共20頁(yè)。細(xì)胞外→細(xì)胞內(nèi)06細(xì)胞膜GLUT1/3葡萄糖IR胰島素IRSPI3KPIP2PIP3MAPKGSK-3β認(rèn)知障礙HBPUDP-GlcNacTau蛋白PPPGGGUDP(Tau蛋白GGGGGGPPPPPPNFTsAβ第七頁(yè)，共20頁(yè)。大綱論文報(bào)告會(huì)01020304介紹相關(guān)研究藥物總結(jié)0307第八頁(yè)，共20頁(yè)。藥物研究08治療糖尿病藥物共同作用靶點(diǎn)藥二甲雙胍？胰島素胰高血糖素樣肽-1二肽基肽酶抑制劑-4噻唑烷二酮類胰島淀粉樣多肽磺酰脲類非磺酰尿類促泌劑瘦素第九頁(yè)，共20頁(yè)。大綱論文報(bào)告會(huì)01020304介紹相關(guān)研究藥物研究總結(jié)0409第十頁(yè)，共20頁(yè)?？偨Y(jié)ADT2D疾病特點(diǎn)發(fā)病機(jī)制ADT2D糖代謝紊亂胰島素通路受損血管損傷AD胰島素胰高血糖素樣肽-1噻唑烷二酮類第十一頁(yè)，共20頁(yè)。懇請(qǐng)指正！第十二頁(yè)，共20頁(yè)。參考文獻(xiàn)

[1]. WorldAlzheimerReport2015:TheGlobalImpactofDementia|Alzheimer'sDiseaseInternational.2016.[2]. Jia,J.,etal.,TheprevalenceofdementiainurbanandruralareasofChina.Alzheimer's&Dementia,2014.10(1):p.1-9.[3]. Guariguata,L.,etal.,Globalestimatesofdiabetesprevalencefor2013andprojectionsfor2035.DiabetesResearchandClinicalPractice.103(2):p.137-149.[4]. Xu,Y.,etal.,PRevalenceandcontrolofdiabetesinchineseadults.JAMA,2013.310(9):p.948-959.[5]. GBD,M.A.C.O.,Global,regional,andnationalage-sexspecificall-causeandcause-specificmortalityfor240causesofdeath,1990-2013:asystematicanalysisfortheGlobalBurdenofDiseaseStudy2013.Lancet,2014.385(9963):p.117-171.[6]. Ballard,C.,etal.,Alzheimer'sdisease.TheLancet.377(9770):p.1019-1031.[7]. 劉曉燕與張志珺,Tau蛋白在阿爾茨海默病中的研究進(jìn)展.中華腦血管病雜志(電子版),2011(05):第411-416頁(yè).[8]. Fjell,A.M.,etal.,Whatisnormalinnormalaging?Effectsofaging,amyloidandAlzheimer'sdiseaseonthecerebralcortexandthehippocampus.ProgressinNeurobiology,2014.117:p.20-40.[9]. Korf,E.S.C.,etal.,BrainAginginVeryOldMenWithType2Diabetes:TheHonolulu-AsiaAgingStudy.DiabetesCare,2006.29(10):p.2268-2274.第十三頁(yè)，共20頁(yè)。參考文獻(xiàn)[10]. vanElderen,S.G.,etal.,Progressionofbrainatrophyandcognitivedeclineindiabetesmellitus:a3-yearfollow-up.Neurology,2010.75(11):p.997-1002.[11]. Profenno,L.A.,A.P.PorsteinssonandS.V.Faraone,Meta-AnalysisofAlzheimer'sDiseaseRiskwithObesity,Diabetes,andRelatedDisorders.BiologicalPsychiatry,2010.67(6):p.505-512.[12]. Gudala,K.,etal.,Diabetesmellitusandriskofdementia:Ameta‐analysisofprospectiveobservationalstudies.JournalofDiabetesInvestigation,2013.4(6):p.640-650.[13]. Sims-Robinson,C.,etal.,HowdoesdiabetesaccelerateAlzheimerdiseasepathology?Naturereviews.Neurology,2010.6(10):p.551-559.[14]. Erus,G.,etal.,SpatialPatternsofStructuralBrainChangesinType2DiabeticPatientsandTheirLongitudinalProgressionWithIntensiveControlofBloodGlucose.DiabetesCare,2014.38(1):p.97-104.[15]. Moran,C.,etal.,BrainAtrophyinType2Diabetes:Regionaldistributionandinfluenceoncognition.DiabetesCare,2013.36(12):p.4036-4042.[16]. Yang,S.,etal.,Alternativemitochondrialelectrontransferforthetreatmentofneurodegenerativediseasesandcancers:Methyleneblueconnectsthedots.ProgressinNeurobiology.[17]. Gray,S.M.,R.I.MeijerandE.J.Barrett,InsulinRegulatesBrainFunction,butHowDoesItGetThere?Diabetes,2014.63(12):p.3992-3997.第十四頁(yè)，共20頁(yè)。參考文獻(xiàn)[18]. delaMonte,S.M.,Type3DiabetesisSporadicAlzheimer’sdisease:Mini-Review.Europeanneuropsychopharmacology:thejournaloftheEuropeanCollegeofNeuropsychopharmacology,2014.24(12):p.1954-1960.[19]. Simpson,I.A.,etal.,DecreasedconcentrationsofGLUT1andGLUT3glucosetransportersinthebrainsofpatientswithAlzheimer'sdisease.AnnNeurol,1994.35(5):p.546-51.[20]. Kalaria,R.N.andS.I.Harik,Abnormalitiesoftheglucosetransporterattheblood-brainbarrierandinbraininAlzheimer'sdisease.ProgClinBiolRes,1989.317:p.415-21.[21]. Winkler,E.A.,etal.,GLUT1reductionsexacerbateAlzheimer'sdiseasevasculoneuronaldysfunctionanddegeneration.Natureneuroscience,2015.18(4):p.521-530.[22]. Liu,Y.,etal.,DecreasedglucosetransporterscorrelatetoabnormalhyperphosphorylationoftauinAlzheimerdisease.FEBSletters,2008.582(2):p.359-364.[23]. Liu,Y.,etal.,Brainglucosetransporters,O-GlcNAcylationandphosphorylationoftauindiabetesandAlzheimerdisease.Journalofneurochemistry,2009.111(1):p.242-249.[24]. Jin,N.,etal.,CREBregulatestheexpressionofneuronalglucosetransporter3:apossiblemechanismrelatedtoimpairedbrainglucoseuptakeinAlzheimer’sdisease.NucleicAcidsResearch,2013.41(5):p.3240-3256.[25]. Correia,S.C.,etal.,Insulinsignaling,glucosemetabolismandmitochondria:MajorplayersinAlzheimer'sdiseaseanddiabetesinterrelation.BrainResearch,2012.1441:p.64-78.[26]. Srikanth,V.,etal.,AdvancedglycationendproductsandtheirreceptorRAGEinAlzheimer'sdisease.NeurobiologyofAging,2011.32(5):p.763-777.第十五頁(yè)，共20頁(yè)。參考文獻(xiàn)[27]. Kuhla,A.,etal.,AdvancedglycationendproductsaremitogenicsignalsandtriggercellcyclereentryofneuronsinAlzheimer'sdiseasebrain.NeurobiologyofAging,2015.36(2):p.753-761.[28]. More,S.S.,A.P.VartakandR.Vince,RestorationofGlyoxalaseEnzymeActivityPrecludesCognitiveDysfunctioninaMouseModelofAlzheimer’sDisease.ACSChemicalNeuroscience,2012.4(2):p.330-338.[29]. delaMonte,S.M.andM.Tong,BrainmetabolicdysfunctionatthecoreofAlzheimer'sdisease.BiochemicalPharmacology,2014.88(4):p.548-559.[30]. DeFelice,F.G.,Alzheimer’sdiseaseandinsulinresistance:translatingbasicscienceintoclinicalapplications.TheJournalofClinicalInvestigation,2013.123(2):p.531-539.[31]. Dineley,K.T.,J.B.JahrlingandL.Denner,InsulinresistanceinAlzheimer'sdisease.NeurobiologyofDisease,2014.72,PartA:p.92-103.[32]. Garcia-Casares,N.,etal.,Structuralandfunctionalbrainchangesinmiddle-agedtype2diabeticpatients:across-sectionalstudy.JAlzheimersDis,2014.40(2):p.375-86.[33]. Baker,L.D.,etal.,InsulinresistanceandAlzheimer-likereductionsinregionalcerebralglucosemetabolismforcognitivelynormaladultswithprediabetesorearlytype2diabetes.ArchNeurol,2011.68(1):p.51-7.[34]. Willette,A.A.,etal.,AssociationofInsulinResistanceWithCerebralGlucoseUptakeinLateMiddle-AgedAdultsatRiskforAlzheimerDisease.JAMANeurol,2015.72(9):p.1013-20.第十六頁(yè)，共20頁(yè)。參考文獻(xiàn)[35]. Ishibashi,K.,etal.,Reduceduptakeof18F-FDGand15O-H2OinAlzheimer'sdisease-relatedregionsafterglucoseloading.JCerebBloodFlowMetab,2015.35(8):p.1380-5.[36]. Ishibashi,K.,etal.,RelationshipBetweenAlzheimerDisease–LikePatternof18F-FDGandFastingPlasmaGlucoseLevelsinCognitivelyNormalVolunteers.JournalofNuclearMedicine,2015.56(2):p.229-233.[37]. Ishibashi,K.,etal.,PlasmaGlucoseLevelsAffectCerebral18F-FDGDistributioninCognitivelyNormalSubjectsWithDiabetes.ClinNuclMed,2016.[38]. Calvo-Ochoa,E.andC.Arias,CellularandmetabolicalterationsinthehippocampuscausedbyinsulinsignallingdysfunctionanditsassociationwithcognitiveimpairmentduringagingandAlzheimer'sdisease:studiesinanimalmodels.Diabetes/MetabolismResearchandReviews,2015.31(1):p.1-13.[39]. Deng,Y.,etal.,DysregulationofInsulinSignaling,GlucoseTransporters,O-GlcNAcylation,andPhosphorylationofTauandNeurofilamentsintheBrain:ImplicationforAlzheimer’sDisease.TheAmericanJournalofPathology,2009.175(5):p.2089-2098.[40]. Kadavath,H.,etal.,Taustabilizesmicrotubulesbybindingattheinterfacebetweentubulinheterodimers.ProcNatlAcadSciUSA,2015.112(24):p.7501-6.[41]. Frost,B.,J.G?tzandM.B.Feany,Connectingthedotsbetweentaudysfunctionandneurodegeneration.TrendsinCellBiology.25(1):p.46-53.[42]. 劉曉燕與張志珺,Tau蛋白在阿爾茨海默病中的研究進(jìn)展.中華腦血管病雜志(電子版),2011(05).第十七頁(yè)，共20頁(yè)。參考文獻(xiàn)[43]. Selkoe,D.J.,Alzheimer'sDisease:Genes,Proteins,andTherapy.PhysiologicalReviews,2001.81(2):p.741-766.[44]. Salahuddin,P.,etal.,Structureofamyloidoligomersandtheirmechanismsoftoxicities:Targetingamyloidoligomersusingnoveltherapeuticapproaches.EurJMedChem,2016.114:p.41-58.[45]. Ma,L.,J.WangandY.Li,Insulinresistanceandcognitivedysfunction.ClinicaChimicaActa,2015.444:p.18-23.[46]. Zhang,H.,etal.,IntranasalInsulinEnhancedResting-StateFunctionalConnectivityofHippocampalRegionsinType2Diabetes.Diabetes,2014.64(3):p.1025-1034.[47]. Thambisetty,M.,etal.,ImpairedGlucoseToleranceinMidlifeandLongitudinalChangesinBrainFunctionDuringAging.Neurobiologyofaging,2013.34(10):p.2271-2276.[48]. TraumaticBrainInjury,Microglia,andBetaAmyloid.InternationalJournalofAlzheimer'sDisease,2012.2012:p.5.[49]. Hort,J.,etal.,EFNSguidelinesforthediagnosisandmanagementofAlzheimer’sdisease.2010,BlackwellPublishingLtd.p.1236--1248.[50]. Schmidt,R.,etal.,EFNS-ENS/EANGuidelineonconcomitantuseofcholinesteraseinhibitorsandmemantineinmoderatetosevereAlzheimer'sdisease.2015.p.889--898.[51]. 張志珺,王.A.任.A.,SSRI類抗抑郁劑在阿爾茨海默病中的應(yīng)用研究進(jìn)展.東南大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2014(04):第504-508頁(yè).第十八頁(yè)，共20頁(yè)。參考文獻(xiàn)[52]. Yu,Y.,etal.,Insulinsensitizersimprovelearningandattenuatetauhyperphosphorylationandneuroinflammationin3xTg-ADmice.JournalofNeuralTransmission,2014.122(4):p.593-606.[53]